Opiate Receptors and Antagonists: From Bench to Clinic - Paperback

EAN (ISBN-13): 9781617378225
ISBN (ISBN-10): 1617378224
Hardcover
Paperback
Publishing year: 2010
Publisher: Humana
523 Pages
Weight: 1,129 kg
Language: eng/Englisch

Book in our database since 2012-07-14T06:32:32+01:00 (London)
Detail page last modified on 2023-10-31T09:42:37+00:00 (London)
ISBN/EAN: 9781617378225

ISBN - alternate spelling:
1-61737-822-4, 978-1-61737-822-5
Alternate spelling and related search-keywords:
Book title: opiate receptors and antagonists from bench clinic

---

Information from Publisher

Author: Reginald Dean; Edward J. Bilsky; S. Stevens Negus
Title: Contemporary Neuroscience; Opiate Receptors and Antagonists - From Bench to Clinic
Publisher: Humana; Humana Press
757 Pages
Publishing year: 2010-11-19
Totowa; NJ; US
Printed / Made in
Weight: 1,132 kg
Language: English
160,49 € (DE)
164,99 € (AT)
177,00 CHF (CH)
POD
XXIII, 757 p.

BC; Pharmacology/Toxicology; Hardcover, Softcover / Medizin/Pharmazie; Pharmakologie; Verstehen; Antag; Antagonists; Bench; Clinic; Contemporary; Dean; Ethanol; Neuroscience; Opiate; Opioid; Receptors; marijuana; Pharmacology; BB

OPIOID RECEPTORS.- Ultra-Low Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance.- Upregulation of Opioid Receptors.- Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders.- Opioid Receptor Antagonists-Mediated Signaling in Immune System.- OPIOID ANTAGONISTS: CHEMISTRY AND PHARMACOLOGY.- The Chemistry and Pharmacology of Mu Opioid Antagonists.- Medicinal Chemistry of Kappa Antagonists.- The Pharmacology of Delta Opioid Antagonists.- Novel Opioid Antagonists with Mixed/Dual Selectivity.- Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists.- Methylnaltrexone: A Peripherally Acting Opioid Antagonist.- SUBSTANCE ABUSE.- Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration.- Naltrexone for Initiation and Maintenance of Opiate Abstinence.- Ultra-Low Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids.- Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse of µ-Agonist Opiates?.- Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine.- Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence.- Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions.- ALCOHOL AND INGESTIVE BEHAVIORS.- Opioid Antagonists and Ethanol’s Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies.- Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence.- Preclinical Effects of Opioid Antagonists on Feeding and Appetite.- CNS Opiate Systems and Eating Disorders.- BEHAVIORAL DISORDERS.- Potential Utility of Kappa Ligands in the Treatment of Mood Disorders.- Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania.- Efficacy of Opioid Antagonists in Attenuating Self-Injurious Behavior.- Pharmacotherapeutic Effects of OpioidAntagonists in Alcohol Abusing Patients with Schizophrenia.- MEDICAL INDICATIONS.- Current Issues in the Use of Opioid Antagonists.- Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose.- Kappa Opioid Antagonists as Pruritogenic Agents.- Clinical Effect of Opioid Antagonists on Clinical Pruritus.- Effects of Opioid Antagonists on L-Dopa-Induced Dyskinesia in Parkinson’s Disease.- Endocrine Effects of Opioid Antagonists.- Opioid Antagonists in Traumatic Shock: Animal and Human Studies.- The Efficac y of Opioid Antagonists against Heatstroke-Induced Ischemia and Injury in Rats.- A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasm.- DRUG DELIVERY APPROACHES.- Non-Clinical Pharmacology of VIVITROL®: A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence.- The Development of Sustained Release Naltrexone and Clinical Use in Treating Opiate Dependency.- The Development of Proneura Technology for the Treatment of Addictions.- Development of Opioid Transdermal Delivery Systems.- Intranasal Naloxone for Treatment of Opioid Overdose.